Shang‐Jyh Hwang

Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial

Brad H. Rovin, Jonathan Barratt, Hiddo J.L. Heerspink et al. · The Lancet · 2023 · 224 citations · Full text

Incidence, prevalence and mortality trends of dialysis end-stage renal disease in Taiwan from 1990 to 2001: the impact of national health insurance

Wancai Yang, Shang‐Jyh Hwang · Nephrology Dialysis Transplantation · 2008 · 208 citations · Full text

High Prevalence and Low Awareness of CKD in Taiwan: A Study on the Relationship Between Serum Creatinine and Awareness From a Nationally Representative Survey

Chih‐Cheng Hsu, Shang‐Jyh Hwang, Chi Pang Wen et al. · American Journal of Kidney Diseases · 2006 · 207 citations

Renal Function, Medicine, Kidney Failure +8

Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial

Hiddo J.L. Heerspink, Jai Radhakrishnan, Charles E. Alpers et al. · The Lancet · 2023 · 203 citations · Full text

Glomerulonephritis, Active-controlled Clinical Trial, Renal Function +9

Association of Symptoms of Depression With Progression of CKD

Yi‐Chun Tsai, Yi‐Wen Chiu, Chi‐Chih Hung et al. · American Journal of Kidney Diseases · 2012 · 197 citations

Psychiatry, Mood Symptom, Chronic Disease +6